$1.95
1.04% yesterday
Nasdaq, Jun 25, 10:00 pm CET
ISIN
US74584P1030
Symbol
PULM

Pulmatrix Inc Share price

$1.95
+0.06 3.27% 1M
-0.05 2.26% 6M
+0.09 4.84% YTD
-0.73 27.24% 1Y
-18.85 90.63% 3Y
-16.95 89.68% 5Y
-3,043.05 99.94% 10Y
Nasdaq, Closing price Tue, Jun 25 2024
ISIN
US74584P1030
Symbol
PULM
Sector
Industry

Key figures

Market capitalization $7.12m
Enterprise Value $-570.00k
PER (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.04
EV/Sales (TTM) EV/Sales -0.05
P/S ratio (TTM) P/S ratio 0.61
P/B ratio (TTM) P/B ratio 0.37
Sales growth (TTM) Sales growth 82.28%
Turnover (TTM) Turnover $11.68m
EBIT (operating result TTM) EBIT $-9.41m
Free cash flow (TTM) Free cash flow $-14.61m
Cash position $16.30m
EPS (TTM) EPS $-2.42
P/S ratio expected 1.03
EV/Sales expected negative
Short interest 0.01%
Show more

Is Pulmatrix Inc a top scorer stock according to the dividend, high growth investing or Leverman strategy?

As a free StocksGuide basic user, you can view the scores for all 6,951 shares worldwide.

Pulmatrix Inc Share analysis

Unlock scores for free

Analyst opinions

1 Analyst has issued a forecast Pulmatrix Inc:

1x Buy
100%

Analyst opinions

1 Analyst has issued a forecast Pulmatrix Inc:

Buy
100%

Financial data from Pulmatrix Inc

Profit and loss account P&L | Balance sheet | Cash flow


Quarter TTM Annually
Mar '24
+/-
%
12 12
82% 82%
100%
- Direct costs 1.35 1.35
-
12%
10 10
-
89%
- Selling and administrative expenses 3.40 3.40
16% 16%
29%
- Research and development costs 15 15
16% 16%
128%
-8.06 -8.06
53% 53%
-69%
- Depreciation and amortization 1.35 1.35
14% 14%
12%
EBIT (operating result) EBIT -9.41 -9.41
49% 49%
-81%
Net profit -8.85 -8.85
52% 52%
-76%

Figures in millions USD.

Don't miss a thing! We will send you all news about the Pulmatrix Inc share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

Pulmatrix Inc Share News

Neutral
PRNewsWire
28 days ago
Cross license involves Pulmatrix iSPERSE™ technology and MannKind's Cricket® inhalation device. Pulmatrix transferring leased building, all leasehold improvements, laboratory equipment and other related personal property in exchange for MannKind assumption of lease.
Neutral
PRNewsWire
about one month ago
Orally Inhaled PUR3100 is associated with rapid systemic PK within the therapeutic window and a mean time to Cmax matching intravenously (IV) administered DHE. Self-administered PUR3100 showed improved safety and tolerability relative to IV DHE.
Neutral
PRNewsWire
about 2 months ago
$16.3 million in cash and cash equivalents at the end of Q1 2024 providing projected cash runway into Q1 2026 Third amendment made in Q1 to Cipla partnership results in the wind down of the PUR1900 Phase 2b study and allows for a significant reduction in expected cash burn for Pulmatrix Cipla to take sole responsibility for development of PUR1900, refocused on markets with greatest unmet need a...
More Pulmatrix Inc News

Company profile

Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products for respiratory and other diseases. The firm focuses on the prevention and treatment of respiratory diseases and infections. It offers products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov, and Robert S. Langer, Jr. on June 15, 2015 and is headquartered in Lexington, MA.

Head office United States
CEO Teofilo Raad
Employees 22
Founded 2015
Website www.pulmatrix.com

Register for free

StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.

The Apple share at a glance with charts, current key figures, news and share analyses.
The best dividend stocks in the dividend top scorer list.
Stock analyses of the best stocks worldwide.
Build wealth now